Tranexamic%25252525252525252525252525252525252525252525252525252525252525252525252525252520acid

# Tranexamic Acid ## Overview Tranexamic acid (TXA) is a synthetic lysine analog that acts as an antifibrinolytic agent by competitively inhibiting the activation of plasminogen to plasmin, thereby preventing clot degradation. ## Primary Indications * **Trauma:** Hemorrhagic shock (CRASH-2 protocol). * **Surgery:** Reduction of periprocedural blood loss (e.g., cardiac, orthopedic, gynecologic). * **Obstetrics:** Postpartum hemorrhage. * **Emergency Medicine:** Epistaxis, menorrhagia, traumatic hyphema. ## Adult Dosing * **Trauma:** 1 g IV loading dose over 10 minutes, followed by 1 g IV infusion over 8 hours. Administer as soon as possible, ideally within 3 hours of injury. * **Menorrhagia:** 1.3 g PO TID for up to 5 days during menstruation. * **Surgical Prophylaxis:** Dosing varies widely by procedure (typically 10–30 mg/kg IV). Consult institutional guidelines. ## Pediatric Dosing * **Trauma:** 15 mg/kg IV (max 1 g) loading dose, followed by 2 mg/kg/hour infusion for 8 hours (or per trauma protocol). * **Standard Off-Label Use:** 10–25 mg/kg IV every 6–8 hours depending on indication. *Dosing is highly protocol-dependent; verify with pediatric weight-based guidelines.* ## Dose Adjustments * **Renal Impairment:** Required. Reduce dose by 50% for CrCl 30–50 mL/min; 75% for CrCl 10–30 mL/min; and 85–90% for CrCl <10 mL/min or hemodialysis. * **Hepatic Impairment:** No specific adjustment necessary. ## Contraindications * **Active Thromboembolic Disease:** History of DVT, PE, or intracranial thrombosis. * **Hypersensitivity:** Known allergy to TXA. * **Subarachnoid Hemorrhage:** Risk of cerebral vasospasm. * **Defective Color Vision:** Acquired dyschromatopsia. ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain. * **Serious:** Thromboembolic events (DVT, PE, MI, stroke), seizures (particularly with high doses or rapid IV bolus), allergic reactions, and visual disturbances. ## Key Drug Interactions * **Thrombolytics/Factor IX Complex:** Concurrent use may theoretically antagonize the efficacy of thrombolytic therapy or increase the risk of thrombosis with pro-coagulant agents. * **Estrogens:** Increased risk of thrombosis if used concomitantly with oral contraceptives. ## Monitoring * **Clinical:** Monitor for signs of thromboembolism (leg swelling, chest pain, dyspnea) and seizure activity. * **Laboratory:** Renal function tests in patients with long-term use. ## Clinical Pearls * **Seizure Risk:** Do not exceed recommended infusion rates; rapid IV injection increases seizure risk, even in patients without a history of epilepsy. * **Timing:** Efficacy in trauma significantly decreases if administered >3 hours post-injury. * **Stability:** Once diluted, IV solutions are generally stable for 24 hours at room temperature. * **Off-Label:** Frequently used topically (e.g., soaked gauze for epistaxis) or orally (off-label compounding) for mucosal bleeding. *** **Disclaimer:** This information is for educational purposes and does not replace professional clinical judgment. Always verify dosages, contraindications, and administration protocols against current hospital formulary, institutional guidelines, and the manufacturer’s package insert before prescribing or administering medication.